A Phase 1b, Single-center, Double-blind, Randomized, Placebo-controlled Study on the Safety, Tolerability, and Pharmacokinetic Effects of Multiple Doses of LX4211 400 mg qd and LX4211 800 mg qd in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2013
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- 10 Oct 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Aug 2013 New trial record